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ABSTRACT
Objective: To assess the adequacy of reporting of non-
inferiority trials alongside the consistency and utility of
current recommended analyses and guidelines.
Design: Review of randomised clinical trials that used
a non-inferiority design published between January
2010 and May 2015 in medical journals that had an
impact factor >10 (JAMA Internal Medicine, Archives
Internal Medicine, PLOS Medicine, Annals of Internal
Medicine, BMJ, JAMA, Lancet and New England Journal
of Medicine).
Data sources: Ovid (MEDLINE).
Methods: We searched for non-inferiority trials and
assessed the following: choice of non-inferiority margin
and justification of margin; power and significance level
for sample size; patient population used and how this
was defined; any missing data methods used and
assumptions declared and any sensitivity analyses used.
Results: A total of 168 trial publications were included.
Most trials concluded non-inferiority (132; 79%). The
non-inferiority margin was reported for 98% (164), but
less than half reported any justification for the margin
(77; 46%). While most chose two different analyses
(91; 54%) the most common being intention-to-treat
(ITT) or modified ITT and per-protocol, a large number
of articles only chose to conduct and report one
analysis (65; 39%), most commonly the ITT analysis.
There was lack of clarity or inconsistency between the
type I error rate and corresponding CIs for 73 (43%)
articles. Missing data were rarely considered with (99;
59%) not declaring whether imputation techniques were
used.
Conclusions: Reporting and conduct of non-inferiority
trials is inconsistent and does not follow the
recommendations in available statistical guidelines,
which are not wholly consistent themselves. Authors
should clearly describe the methods used and provide
clear descriptions of and justifications for their design
and primary analysis. Failure to do this risks misleading
conclusions being drawn, with consequent effects on
clinical practice.
INTRODUCTION
Non-inferiority trials assess whether a new
intervention is not much worse when
compared to a standard treatment or care.
These trials answer whether we are willing to
accept a new intervention that may be clinic-
ally worse, yet still be beneﬁcial for patients
while having another advantage, such as
less-intensive treatment, lower cost or fewer
side effects.1 Non-inferiority and equivalence
are sometimes, mistakenly, used interchange-
ably. Equivalence trials are designed to show
that a new intervention performs not much
worse and not much better than a standard
intervention. Both trial designs are different
to superiority trials, which aim to show that a
new intervention performs better when com-
pared to a control.
Poor trial quality can bias trial results
towards concluding no difference between
treatments.2 This creates more challenges in
non-inferiority trials than superiority trials as
such bias can produce false-positive results
for non-inferiority.3–5 The increasing use of
this design6–8 means that it is even more
important for trialists to understand the
Strengths and limitations of this study
▪ This research clearly demonstrates the inconsist-
ency in recommendations for non-inferiority
trials provided by guidelines for researchers and
this is reflected within this review.
▪ It highlights missing data and sensitivity ana-
lyses in the context of non-inferiority trials.
▪ It provides recommendations using examples for
researchers using the non-inferiority design.
▪ Justification of the choice of the margin was
recorded as such if any attempt was made to do
so, and so one could argue that inadequate
attempts were counted as a ‘justification’;
however, there was good agreement between
reviewers when independently assessed.
▪ Only one reviewer extracted information from all
articles and therefore assessments may be sub-
jective. However, there was good agreement
when a random 5% of papers were independ-
ently assessed.
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issues around the quality in the design and analysis of
non-inferiority trials.
There are several guidelines available to aid research-
ers using a non-inferiority design, where various consid-
erations of the design are explained and discussed
(table 1).
1. The CONSORT extension statements1 9 focus on the
reporting of non-inferiority trials, with the most
recent 2012 statement being an elaboration of the
2006 statement.
2. The draft FDA 20102 document focuses on all aspects
and issues relative to non-inferiority trials and gives
general guidance.
3. The EMEA 2000 guideline10 discusses switching
between non-inferiority and superiority designs and
the EMEA 200611 guideline discusses the choice of
the non-inferiority margin, taking into account
two-arm and three-arm trials.
4. The ICH E9 and E10 guidelines12 13 are general stat-
istical guidance documents addressing issues for all
clinical trials and designs.
5. SPIRIT14 is a guidance document for protocols for all
trial designs and includes discussions of recently
developed methodology.
There is some inconsistency between these guidelines
regarding the conduct of non-inferiority trials (table 1)
that may adversely affect the overall quality and report-
ing of non-inferiority trials. Non-inferiority trials require
more care around certain issues, and so clear guidance
on how to design and analyse these trials are necessary.
Some of these issues that can inﬂuence inferences made
about non-inferiority are outlined below.
First, the non-inferiority margin—the value that allows
for a new treatment to be ‘acceptably worse’1—is used as
a reference for conclusions about non-inferiority. It is
recommended by all guidelines that this margin is
chosen on a clinical basis, meaning the maximum clinic-
ally acceptable extent to which a new drug can be less
effective than the standard of care and still show evi-
dence of an effect.15 However, it is unclear whether stat-
istical considerations should also affect the choice of an
appropriate margin, as recommended by the Draft FDA
2010, ICH E10 and EMEA 2006 guidelines2 11 13
(table 1). Ignoring statistical evidence from
meta-analyses or systematic reviews could have the poten-
tial for researchers to choose an unrealistic margin.
Second, it is important to choose who is included in
analyses for non-inferiority trials. The intention-to-treat
(ITT) analysis (includes all randomised patients irre-
spective of postrandomisation occurrences) is preferred
for superiority trials as it is likely to lead to a treatment
effect closer to having no effect and so is conservative.16
For non-inferiority trials, the ITT analysis can bias
towards the null, which may lead to false claims of non-
inferiority.17 The alternative per-protocol (PP) analysis is
often considered instead. However, given that the PP
analysis allows for the exclusion of patients, it fails to
preserve a balance of patient numbers between treat-
ment arms (ie, randomisation) that ITT analysis does
and can cause bias in either direction, depending on
who the analysis excludes.18 Guidelines often recom-
mend performing the ITT and PP analyses, although
deﬁnitions are inconsistent (table 1). In particular, the
CONSORT 2006 guidelines describe the PP analysis as
excluding patients not taking allocated treatment or
otherwise not protocol-adherent,1 whereas the ICH E9
guidelines state that the PP analysis is a “subset of
patients who complied sufﬁciently with the protocol,
such as exposure to treatment, availability of measures
and absence of major protocol violations.”19 These
obscure deﬁnitions could lead researchers to arbitrarily
exclude patients from analyses. The draft FDA guidelines
recommend researchers to use an ITT and as-treated
analysis, although it is unclear what is meant by
‘as-treated’ as this is not deﬁned within the guidelines.
Other frequently used classiﬁcations such as modiﬁed
ITT (mITT), which aims to contain ‘justiﬁable’
exclusions (eg, patients who never had the disease of
interest) from the ITT analysis, are also deﬁned incon-
sistently.20 Third, while two-sided 95% CIs are widely
used for superiority trials, there is some inconsistent
advice as whether to calculate 90% or 95% CIs for non-
inferiority trials and whether these should be presented
as one-sided or two-sided intervals (table 1).
Fourth, the handling of missing data is generally dis-
cussed for all trials but rarely in the speciﬁc context of
non-inferiority trials. Methods recommended to handle
missing data vary between guidelines. The ICH E9
guidelines recommend using a last observation carried
forward imputation method,19 and the more recent
SPIRIT guidelines recommend multiple imputation, but
caution the reader that it relies on untestable assump-
tions14 (table 1). Methods to handle missing data often
contain untestable assumptions and so, sensitivity ana-
lyses are essential to test the robustness of conclusions
under different assumptions.12 However, it is unclear
what sensitivity analyses are appropriate for non-
inferiority trials.
Given the inconsistency between guidelines, we
hypothesised that poor conduct and reporting would be
associated with demonstrating non-inferiority. This
review investigates the quality of conduct and reporting
for non-inferiority trials in a selection of high-impact
journals over a 5-year period. We also provide recom-
mendations to aid trialists who may consider a non-
inferiority design.
METHODS
Medical journals (general and internal medicine) with
an impact factor >10 according to the ISI web of knowl-
edge21 were included in the review (correct at time of
search on 31 May 2015), the rationale being that articles
published in these journals are likely to have the highest
inﬂuence on clinical practice and be the most rigorously
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Table 1 Summary of guidelines
Justification of margin Who is included in analysis CI Missing data Sensitivity analyses
CONSORT 20061 ‘Margin should be
specified and preferably
justified on clinical
grounds’
‘Non-ITT analyses might be
desirable as a protection from
ITTs increase in type I error.
There is greater confidence in
results when the conclusions are
consistent’.
ITT: ‘Analysing all patients within
their randomised groups,
regardless of whether they
completed allocated treatment is
recommended’
PP: ‘Alternative analyses that
exclude patients not taking
allocated treatment or otherwise
not protocol-adherent could bias
the trial in either direction. The
terms on-treatment or PP
analysis are often used but may
be inadequately defined’.
‘Many non-inferiority
trials based their
interpretation on the upper
limit of a one-sided 97.5%
CI, which is the same as
the upper limit of a
two-sided 95% CI’.
‘Although one-sided and
two-sided CIs allow for
inferences about
non-inferiority, we suggest
that two-sided CIs are
appropriate in most
non-inferiority trials. If a
one-sided 5% significance
level is deemed
acceptable for the
non-inferiority hypothesis
test (a decision open to
question), a 90%
two-sided CI could then be
used’.
CONSORT 20129 ‘Should be indicated if
conclusions are related to PP
analysis, ITT analysis or both
and if the conclusions are stable
between them’.
‘The two-sided CI provides
additional information, in
particular for the situation
in which the new treatment
is superior to the reference
treatment’
Sensitivity analysis is
discussed through an
example: ‘Study endpoints
were analysed primarily for
the PP population and
repeated, for sensitivity
reasons, for the ITT
population’.
Draft FDA 20102 ‘Whether M1 (the effect of
the active control arm
relative to placebo) is
based on a single study or
multiple studies, the
observed (if there were
multiple studies) or
anticipated (if there is only
one study) statistical
variation of the treatment
effect size should
‘It is therefore important to
conduct both ITT and
“as-treated” analyses in
non-inferiority studies’.
ITT: ‘preserve the principle that
all patients are analysed
according to the treatment to
which they have been
randomised even if they do not
receive it’
‘Typically, the one-sided
type I error is set at 0.025,
by asking that the upper
bound of the 95% CI for
control treat be less than
the NI margin. If multiple
studies provide very
homogeneous results for
one or more important
endpoints, it may be
possible to use the 90%
‘Poor quality can reduce
the drug’s effect size
and undermine the
assumption of the effect
size of the control agent,
giving the study a “bias
towards the null”’.
Continued
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Table 1 Continued
Justification of margin Who is included in analysis CI Missing data Sensitivity analyses
contribute to the ultimate
choice of M1, as should
any concerns about
constancy. The selection
of M2 (the largest
clinically acceptable
difference of the test
treatment compared to the
active control) is then
based on clinical
judgment regarding how
much of the M1 active
comparator treatment
effect can be lost. The
exercise of clinical
judgment for the
determination of M2
should be applied after
the determination of M1
has been made based on
the historical data and
subsequent analysis’
lower bound rather than
the 95% lower bound of
the CI to determine the
active control effect size’
ICH E912 ‘This margin is the largest
difference that can be
judged as being clinically
acceptable’
‘In confirmatory trials, it is usually
appropriate to plan to conduct an
analysis of the full analysis set
and a PP analysis. In an
equivalence or non-inferiority
trial, use of the full analysis set is
generally not conservative and
its role should be considered
very carefully’.
ITT: ‘participants allocated to a
treatment group should be
followed up, assessed and
analysed as members of that
group irrespective of their
compliance to the planned
course of treatment’.
Full analysis set: ‘The set of
participants that is as close as
possible to the ideal implied by
‘For non-inferiority trials, a
one-sided interval should
be used. The choice of
type I error should be a
consideration separate
from the use of a
one-sided or two-sided
procedure’.
‘Imputation techniques,
ranging from LOCF to
the use of complex
mathematical models,
may be used to
compensate for missing
data’
‘An investigation should be
made concerning the
sensitivity of the results of
analysis to the method of
handling missing values,
especially if the number of
missing values is
substantial’.
Continued
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Table 1 Continued
Justification of margin Who is included in analysis CI Missing data Sensitivity analyses
the ITT principle. It is derived
from the set of all randomised
participants by minimal and
justified elimination of
participants’.
PP: ‘The set of data generated
by the subset of participants who
complied with the protocol
sufficiently to ensure that these
data would be likely to exhibit the
effects of treatment, according to
the underlying scientific model.
Compliance covers such
considerations as exposure to
treatment, availability of
measurements and absence of
major protocol violations’.
ICH E1013 ‘The determination of the
margin in a non-inferiority
trial is based on statistical
reasoning and clinical
judgment’
SPIRIT14 Use an example where
‘non-inferiority would be claimed
if ITT and PP analyses show
conclusions of NI’.
ITT: ‘To preserve the unique
benefit of randomisation as a
mechanism to avoid selection
bias, an “as randomised’
analysis retains participants in
the group to which they were
originally allocated. To prevent
attrition bias, outcome data
obtained from all participants are
included in the data analysis,
regardless of protocol
adherence’.
PP and mITT: ‘Some trialists use
other types of data analyses
‘Multiple imputation can
be used to handle
missing data although
relies on untestable
assumptions’
‘Sensitivity analyses are
highly recommended to
assess the robustness of
trial results under different
methods of handling
missing data’
Continued
RehalS,etal.BM
J
Open
2016;6:e012594.doi:10.1136/bm
jopen-2016-012594
5
O
p
e
n
A
c
c
e
s
s
group.bmj.com
 o
n
 August 24, 2017 - Published by 
http://bmjopen.bmj.com/
D
ow
nloaded from
 
Table 1 Continued
Justification of margin Who is included in analysis CI Missing data Sensitivity analyses
(commonly labelled as “mITT” or
“PP”) that exclude data from
certain participants—such as
those who are found to be
ineligible after randomisation or
who deviate from the intervention
or follow-up protocols. This
exclusion of data from protocol
non-adherers can introduce bias,
particularly if the frequency of
and the reasons for
non-adherence vary between the
study groups’.
EMEA 200611 ‘The choice of delta must
always be justified on
clinical and statistical
grounds’
‘A two-sided 95% CI (or
one-sided 97.5% CI) is
constructed. The interval
should lie entirely on the
positive side of the margin.
Statistical significance is
generally assessed using
the two-sided 0.05 level of
significance (or one-sided
0.025)’
EMEA 200010 ‘ITT and PP analyses have equal
importance and their use should
lead to similar conclusions for
robust interpretation’
‘A two-sided CI should lie
entirely to the right of
delta. If one-sided
confidence is used then
97.5% should be used’
‘It will be necessary to pay
particular attention to
demonstrating the
sensitivity of the trial by
showing similar results for
the full analysis set and
PP analysis set’
ITT, intention to treat; LOCF, last observation carried forward; mITT, modified intention to treat; NI, non-inferiority; PP, per-protocol.
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conducted and reported due to the thorough editorial
process. We searched Ovid (MEDLINE) using the search
terms ‘noninferior’, ‘non-inferior’, ‘noninferiority’ and
‘non-inferiority’ in titles and abstracts between 1 January
2010 and 31 May 2015 in New England Journal of Medicine
(NEJM), Lancet, JAMA, British Medical Journal, Annals of
Internal Medicine, PLOS Medicine and Archives of Internal
Medicine (descending impact order). From 2013, Archives
of Internal Medicine was renamed JAMA Internal Medicine,
and, therefore, both journals have been included in this
review. All journals refer authors to the CONSORT state-
ment and checklist when reporting. Eligibility of articles
was assessed via abstracts by two reviewers (SR and
TPM). Articles included were non-inferiority rando-
mised controlled clinical trials. Articles were excluded if
the primary analysis was not for non-inferiority.
Systematic reviews, meta-analyses and commentaries
were also excluded. Few trials were designed and ana-
lysed using Bayesian methods and were therefore
excluded for consistent comparability in frequentist
methods.
Before performing the review, a data extraction form
was developed to extract information from articles.
Information extracted was with regard to the primary
outcome. The form was standardised to collect informa-
tion on the year of publication, non-inferiority margin
(and how the margin was justiﬁed), randomisation, type
of intervention, disease area, sample size, analyses per-
formed (how this was deﬁned and what was classed as
primary/secondary), primary outcome, p values (and
whether this was for a superiority hypothesis), signiﬁ-
cance level of CIs (and whether both bounds were
reported), imputation techniques for missing data, sensi-
tivity analyses, conclusions of non-inferiority and
whether a test for superiority was prespeciﬁed.
Justiﬁcations for the choice of the non-inferiority
margin were reviewed by two reviewers (SR and PPJP).
See online supplementary material for further details on
methods.
A quality grading system was developed based on
whether the margin was justiﬁed (yes vs no/poor), how
many analyses were performed on the primary outcome
(<2 vs ≥2) and whether the type I error rate was consist-
ent with the signiﬁcance level of the CI (yes vs no/
unclear). Articles were classed as ‘excellent’ if all these
criteria were fulﬁlled and were classed as ‘poor’ if none
was fulﬁlled. Articles which satisﬁed one criterion were
classed as ‘fair’ and articles that provided two of the
three criteria were classiﬁed as ‘good’. The results of
this grading were compared to inferences on non-
inferiority to assess if the quality of reporting was asso-
ciated with concluding non-inferiority at the 5% signiﬁ-
cance level.
Additional published online supplementary material
was accessed only if it speciﬁcally referred to the infor-
mation we were extracting within articles. As a substudy,
all statistical methods, outcomes and sample sizes from
protocols and/or online supplementary material were
reviewed from NEJM as the journal is known to speciﬁc-
ally request and publish protocols and statistical analysis
plans alongside accepted publications.
Assessments were carried out by one reviewer (SR),
with a random selection of 5% independently reviewed
(PPJP). Any assessments that required a second opinion
were independently reviewed (TPM). Any discrepancies
were resolved by discussion between reviewers.
All analyses were conducted using Stata V.14.
RESULTS
Our search found 252 articles. After duplicate publica-
tions were removed, 217 were screened for eligibility
using their titles and abstracts. A total of 46 articles were
excluded leaving 171 articles to be reviewed. A further
three articles were excluded during the full-text review
leaving 168 articles (ﬁgure 1).
General characteristics of the included studies are
summarised in table 2.
Margin
The non-inferiority margin was speciﬁed in 164 (98%)
articles and was justiﬁed in less than half of articles 76
(45%). The most common justiﬁcation was on a clinical
basis (29 (17%)), which was often worded ambiguously
and with little detail. A total of 14 (8%) used previous
ﬁndings from past trials or statistical reviews to justify the
choice of the margin (table 3).
Patients included in analysis
Over a third of articles 65 (39%) declared only one ana-
lysis (table 3 and see online supplementary table S1a).
The majority of trials classed ITT analysis as primary and
PP analyses as secondary (see online supplementary
ﬁgure S1a). PP analyses were performed in 90 (54%)
trials; of which, 11 (12%) did not deﬁne what was meant
by ‘PP’ (table 3 and see online supplementary table
S1b). Deﬁnitions of the PP population contained
various exclusions, mostly regarding errors in rando-
mised treatment or treatment received.
Type I error rate
Consistency between the type I error rate and CIs
reported was moderate at 95 (57%) (table 4). Most arti-
cles, 69 (41%), used a one-sided 2.5% or (numerically
equivalent) two-sided 5% signiﬁcance level (table 5) and
some used a one-sided 5% signiﬁcance level, 46 (27%).
The majority of articles presented two-sided CIs (147;
88%) and 19 (11%) articles presented one-sided CIs.
Most two-sided CIs were at the 95% signiﬁcance level:
125 (74%).
Missing data and sensitivity analyses
Ninety-nine (59%) trials did not report whether or not
any imputation was carried out and only 12 (7%) expli-
citly declared that no imputation was used. Assuming a
worst-case scenario or multiple imputation were the
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most common methods used (table 6). The number of
imputations used for multiple imputation was speciﬁed
in 8 of 11 articles and 4 of 11 stated at least one of the
assumptions from Rubin’s rules.22 Sixty-four (38%) trials
reported using sensitivity analyses to test robustness of
conclusions of the primary outcome; of these, 27 (42%)
were related to assumptions about the missing data
(table 6).
Study conclusions
There were seven (4%) articles that could not make
deﬁnitive conclusions (noted as ‘other’; table 7). For
example, if all analyses conducted had to demonstrate
non-inferiority to conclude a treatment was non-inferior,
and only one of the analyses did, then non-inferiority
could not be concluded and could not be rejected.
Non-inferiority was declared in 132 (79%) articles. Ten
of these had made some reference with equivalence
studies within the article (see online supplementary
material).
Superiority analyses were performed in 37 (22%) trials
after declaring non-inferiority; of which, 27 (73%) had
explicitly preplanned for superiority analyses. p Values
were reported in 98 (58%) articles; of which, 29 (30%)
were testing a superiority hypothesis.
Subgroup of trials with published protocols
Additional information from protocols published by
NEJM was extracted for 57 of 61 articles. Including this
additional information provided by NEJM improved
reporting of results across all criteria: 39 (64%) articles
justiﬁed the choice of the non-inferiority margin com-
pared to 19 (31%); most planned two or more analyses
45 (74%) compared to 37 (61%) (there were a couple
of cases where two analyses were planned in the proto-
col but only one was stated in the published article);
consistency between type I error rates and CIs was 44
(72%) compared with 36 (59%); imputation techniques
were considered in 29 (48%) compared with 17 (28%)
articles and sensitivity analyses were considered in
38 (62%) articles compared with 25 (41%). The major-
ity of articles concluded non-inferiority with 8 (13%)
not determining non-inferiority. A total of 14 (23%) arti-
cles concluded superiority, of which most were pre-
Figure 1 Flow chart of eligibility
of articles.
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Table 2 General characteristics
All articles (n=168)
Including NEJM
protocols (n=61)
Characteristics n (%) n (%)
Journal
NEJM 61 (36) 61
Lancet 64 (38)
JAMA 19 (11)
BMJ 8 (5)
Annals of Internal Medicine 5 (2)
PLoS Medicine 7 (4)
Archives of Internal Medicine 2 (1)
JAMA of Internal Medicine 2 (1)
Year of publication
2010 26 (15) 9 (15)
2011 27 (16) 9 (15)
2012 29 (17) 8 (13)
2013 39 (23) 19 (31)
2014 27 (16) 10 (16)
2015 20 (12) 6 (10)
Type of intervention
Drug 112 (67) 44 (72)
Surgery 22 (13) 7 (11)
Other 34 (20) 10 (16)
Randomisation
Patient 163 (97) 59 (97)
Cluster 5 (3) 2 (3)
Power
80% 6 (36) 19 (31)
85% 11 (7) 5 (8)
90% 65 (39) 26 (43)
71–99% (excluding the above) 21 (12) 11 (18)
Not reported/unclear 10 (6) 0
Composite outcome
Yes 78 (46) 37 (61)
No 90 (54) 24 (39)
Disease
Heart disease 30 (18) 13 (21)
Blood disorder 19 (11) 6 (10)
Cancer 16 (10) 8 (13)
Diabetes 11 (7) 2 (3)
Thromboembolism 6 (4) 6 (10)
Skin infection (non-contagious) 3 (2) 2 (3)
Urinary tract infection 3 (2) 0
Arthritis 3 (2) 1 (2)
Opthomology 3 (2) 1 (2)
Pneumonia 3 (2) 1 (2)
Complications in pregnancy 3 (2) 0
Stroke 3 (2) 2 (3)
Testing method 3 (2) 1 (2)
Appendicitis 2 (1) 1 (2)
Depression 2 (1) 0
Other non-infectious disease 18 (11) 7 (11)
HIV 18 (11) 2 (3)
Tuberculosis 6 (4) 4 (7)
Malaria 4 (2) 1 (2)
Skin infection (contagious) 2 (1) 0
Hepatitis C 2 (1) 2 (3)
Other infectious disease 8 (5) 1 (2)
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planned (9; 64%). Few articles 8/40 (20%) presented
superiority p values.
Association between quality of reporting and conclusions
Trials that were classed as having some ‘other’ conclu-
sion about non-inferiority were excluded from the ana-
lysis. Overall, there was a suggestive difference between
the quality of reporting and concluding non-inferiority:
x21 ¼ 3:76; p=0.05 (Cochran–Armitage test; table 7).
Trials that were poorly reported were less likely to
conclude non-inferiority than those that satisﬁed two or
all criteria from justifying the choice of the margin,
reporting two or more analyses or reporting a CI consist-
ent with the type I error rate.
DISCUSSION
Reporting of non-inferiority trials is poor and is perhaps
partly due to disagreement between guidelines on vital
issues. There are some aspects that guidelines agree on,
such as a requirement for the non-inferiority margin to
Table 3 Justification of choice of margin, total number of patient populations considered for analyses and patient population
included in the analysis
All articles
(N=168)
Including NEJM
protocols (N=61)
n (%) n (%)
Justification of NI margin
Made no attempt for justification 90 (54) 22 (36)
Clinical basis. No evidence for consultation with external expert group, and no
reference to previous trials of the control arm
32 (19) 11 (18)
Preservation of treatment effect based on estimates of control arm effect from
previous trials
13 (8) 14 (23)
Expert group external to the authors. No reference to previous trials of the control
arm
6 (4) 3 (5)
The same margin as was used in other similar trials 5 (3 2 (3)
10–12% recommended by disease-specific FDA guidelines 4 (2) 1 (2)
General comment that margin was decided according to FDA/regulatory guidance 4 (2) 0
Clinical basis and based on previous similar trial. No evidence for consultation with
external expert group, and no reference to previous trials of the control arm
3 (2) 0
Based on registry/development programme 0 2 (3)
Other* 11 (7) 6 (10)
Number of analyses
One 65 (39) 15 (25)
Two 91 (54) 38 (62)
Three 10 (6) 7 (11)
Not defined 2 (1) 1 (2)
Analysis
ITT 129 (77) 44 (72)
PP 90 (54) 35 (57)
mITT 34 (20) 17 (28)
As-treated 4 (2) 6 (10)
Other 20 (12) 10 (16)
Unclear 2 (1) 2 (3)
*See online supplementary material.
ITT, intention to treat; mITT, modified intention to treat; PP, per-protocol.
Table 4 Consistency of type I error rate with significance levels of CIs over year of publication
Year of publication
2010 2011 2012 2013 2014 2015 Total
All articles (N=168)
Yes 11 (42%) 15 (56%) 15 (52%) 24 (62%) 19 (70%) 11 (55%) 95 (57%)
No 5 (19%) 4 (15%) 4 (14%) 5 (13%) 5 (19%) 3 (15%) 26 (15%)
Not reported 10 (38%) 8 (30%) 10 (34%) 10 (26%) 3 (11%) 6 (30%) 47 (28%)
NEJM subgroup (N=61)
Yes 7 (78%) 6 (67%) 5 (63%) 14 (74%) 8 (80%) 4 (67%) 44 (72%)
No 1 (11%) 2 (22%) 2 (25%) 3 (16%) 2 (20%) 1 (17%) 11 (18%)
Not reported 1 (11%) 1 (11%) 1 (13%) 2 (11%) 0 1 (17%) 6 (10%)
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be justiﬁed, but we ﬁnd that this recommendation is
neglected by the majority of authors. It is remarkable
that several authors performed only one analysis for the
primary outcome and the lack of consistency between
the signiﬁcance level chosen in sample size calculations
and the CI reported further highlights confusion of non-
inferiority trials. Not knowing how to deal with missing
data nor appropriate sensitivity analyses, also adds to the
confusion. The combination of these recent ﬁndings
assessed from high-impact journals and the inconsist-
ency in guidelines indicate: (1) the non-inferiority
design is not well understood by those using the design
and (2) methods for non-inferiority designs are yet to be
optimised.
We anticipated that poor reporting of articles would
bias towards concluding non-inferiority; however, the
poorly reported trials were less likely to demonstrate non-
inferiority. This is somewhat reassuring. Nevertheless, it is
essential to ensure that what is reported at the end of a
trial was prespeciﬁed before the start of a trial: scientiﬁc
credibility and regulatory acceptability of a non-inferiority
trial rely on the trial being well-designed and conducted
according to the design.23 It is possible that the quality of
a trial may also depend on the quality of the outcome;
unresponsive outcomes that miss important differences
between treatments may be intentionally or unintention-
ally chosen to demonstrate non-inferiority. Therefore, it
is also important that the outcome chosen is robust.
Almost 80% of studies concluded non-inferiority,
although it is unclear whether this is due to the reporting
in articles or publication bias. It appears that positive
results (ie, alternative hypotheses) are published more
often, regardless of trial design, as this number is consistent
with other studies that found that more than 70% of pub-
lished superiority trials demonstrated superiority.24 25
More than half of articles reported p values, of which
approximately a third reported p values for a two-sided
test for superiority. p Values, if reported, should be
Table 5 Significance level of (a) type I error rate and (b)
CIs for all articles by whether CI was one-sided or
two-sided
One-sided Two-sided Not reported
(a) Type I error rate (%)
0.8 0 1 (1%) 0
1.25 3 (2) 0 0
2.45 1 (1) 0 0
2.5 40 (24) 2 (1) 2 (1)
5 46 (27) 29 (17) 15 (9)
10 1 (1) 2 (1) 0
Not reported 3 (2) 0 23 (14)
(b) Significance level of CI (%)
90 1 (1) 14 (8) 1 (1)
95 14 (8) 125 (74) 0
97.5 4 (2) 7 (4) 0
Other 0 1 (1) 0
Not reported 0 0 1 (1)
Table 6 Reporting of (a) missing data and (b) sensitivity
analyses
n (%)
(a) Imputation performed
Yes 56 (33)
Worst-case scenario 19 (34)
Multiple imputation 11 (20)
Last observation carried forward 8 (14)
Complete case analysis 6 (11)
Best-case scenario 2 (4)
Last observation carried forward and
worst-case scenario
2 (4)
Best-case/worst-case scenario 3 (5)
Mean imputation 1 (2)
Complete case analysis, multiple imputation
using propensity scores and multiple
imputation using regression modelling
1 (2)
Other and worst-case scenario 1 (2)
Other 1 (2)
No 12 (7)
Not reported 99 (59)
Unclear 1 (1)
Including NEJM protocols (N=61)
Yes 22 (36)
No 7 (11)
Not reported 31 (51)
Unclear 1 (2)
(b) Sensitivity analyses performed
Yes 64 (38)
Patient population 13 (20)
Competing risks 2 (3)
Statistical modelling 2 (3)
Adjusted for baseline variables 1 (2)
Excluded protocol violations 1 (2)
On-treatment 1 (2)
Patient population/other 1 (2)
Unclear 2 (3)
Other 15 (23)
Missing data 27 (42)
Best-case/worst-case scenario 5
Complete case analysis 3
Imputation of missing values 3
Multiple imputation 3
Worst-case scenario 3
Baseline observation carried forward 1
Baseline observation carried forward and
complete case analysis
1
Complete case analysis, multiple imputation
using propensity scores and multiple
imputation using regression modelling
1
Complete case analysis and missing not at
random
1
Complete case analysis and best-case
scenario
1
Different methods 1
Last observation carried forward 1
Modelling 1
Observed failure 1
Worst-case scenario and last observation
carried forward
1
Continued
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calculated for one-sided tests corresponding to the non-
inferiority hypothesis; that is, with H0: δ=margin. p
Values for superiority should not be presented unless
following the demonstration of non-inferiority, where a
preplanned superiority hypothesis is tested.26
Comparison with other studies
The value of the non-inferiority margin was almost
always reported, but more than half of articles made no
attempt to explain how the choice was justiﬁed. While
justiﬁcation of the margin is low, this is actually an
improvement from Schiller et al27 who reported 23%
articles made a justiﬁcation, although this difference
could be because only high-impact journals were
included in this review. There were equally as many arti-
cles that planned and reported an ITT analysis com-
pared with articles that performed ITT and PP analyses.
This is surprising given that CONSORT 2006 states that
an ITT analysis can bias non-inferiority trials towards
showing non-inferiority.1 These results were lower than
found by Wangge et al28 who reported 55% used either
an ITT or PP and 42% used ITT and PP. Most articles
presented two-sided 95% CIs, which is consistent with
results from Le Henanff et al.29
There were very few articles that referred to preserving
the treatment effect based on estimates of the standard
of care arm from previous trials. It is vital that authors
acknowledge this to ensure the standard of care is effect-
ive. If the control was to have no effect at all in the
study, then ﬁnding a small difference between the
standard of care and new intervention would be
meaningless.2
Clinical considerations1 2 9 11–13 to justify the choice of
the margin often had inadequate justiﬁcations, such as
‘deemed appropriate’ or ‘consensus among a group of
clinical experts’. Non-inferiority is only meaningful if it
has strong justiﬁcation in the clinical context and so
should be reported. If the justiﬁcation includes a meas-
urable reduction in adverse events, these should be mea-
sured and the beneﬁt should be demonstrated.
Guidelines recommend that the choice of margin
should be justiﬁed primarily on clinical grounds;
however, previous trials and historical data should also
be considered if available. As an example, Gallagher
et al30 justify the choice of the margin providing as much
information as possible by including references to all
published reports and providing data from the institu-
tion where the senior author is based.
A statement often used in articles reviewed was ‘the
choice of the margin was clinically acceptable’. This
statement does not contain enough information to
justify the choice of the non-inferiority margin. If the
choice of the margin is based on a group of clinical
experts, authors should provide information on how
many experts were involved and how many considered
the choice of the margin being acceptable: a consensus
among a group of 3 clinicians from 1 institution is differ-
ent from a consensus of 20 clinicians representing
several institutions. Radford et al31 justify the choice of
the non-inferiority margin after performing a delegate
survey at a symposium. This method may be a way
forward for researchers to obtain clinical assessment
from a large group of clinicians. Even better would be
to obtain formal assessments, using, for example, the
Delphi method,32 which has been used in the COMET
initiative,33 after presenting the proposed research at a
conference or symposium for clinicians to really engage
with the question at hand.
Deﬁnitions provided by authors were inconsistent
under what they classed as ITT, PP, mITT and as-treated,
for example, “all patients randomised who received at
least one dose of treatment” was deﬁned at least once in
each classiﬁcation. According to the guidelines, the PP
deﬁnition excludes patients from the analysis, but it is
unclear what those exclusions are. The ambiguity of how
PP is deﬁned was evident in this review as deﬁnitions
provided by authors could not be succinctly categorised.
Many articles presented only one analysis, despite
most guidelines recommending at least two ana-
lyses.1 2 9 10 12 Unfortunately, guidelines differ in their
advice on which of the two analyses should be chosen to
Table 6 Continued
n (%)
No 103 (61)
Unclear 1 (1)
Including NEJM protocols
Yes 38 (62)
No 23 (38)
Table 7 Quality of reporting of trials associated with
conclusions of non-inferiority
Concluded non-inferiority
Yes
(N=132)
No
(N=29)
Other
(N=7)
Total
(N=168)
Grade n (%) n (%) n (%) n (%)
Excellent† 11 (73) 2 (13) 2 (13) 15
Good‡ 55 (86) 9 (14) 0 (0) 64
Fair§ 48 (80) 8 (13) 4 (7) 60
Poor¶ 18 (62) 10 (34) 1 (3) 29
*Excluding trials that concluded ‘other’: x21 ¼ 3:76; p=0.05
(Cochran–Armitage test).
†Excellent if margin justified, ≥2 analyses on patient population
performed, type I error rate consistent with significance level of CI.
‡Good if fulfilled two of the following: margin justified, ≥2 analyses
on patient population performed, type I error rate consistent with
significance level of CI.
§Fair if fulfilled one of the following: margin justified, ≥2 analyses
on patient population performed, type I error rate consistent with
significance level of CI.
¶Poor if margin not justified, <2 analyses on patient population
performed, type I error rate not consistent with significance level
of CI.
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base conclusions on. This regrettable, state of affairs was
clearly reﬂected in our review.
The ITT and PP analyses have their biases and so
neither can be taken as a ‘gold standard’ for non-
inferiority trials. The analysis of the primary outcome is
the most important result for any clinical trial. It should
be predeﬁned in the protocol what patients should
adhere to and should be considered at the design stage
what can be carried out to maximise adherence. It
should be made clear exactly who is included in analyses
given the variety of deﬁnitions provided by various
authors, particularly for PP analyses where deﬁnitions are
subjective. Most authors included treatment-related
exclusions such as ‘received treatment’, ‘completed treat-
ment’ or ‘received the correct treatment’. Such differ-
ences in deﬁnitions may be superﬁcially small, but could
in fact make critical differences to the results of a trial.
Poor reporting of whether the hypothesis test was one-
sided or two-sided or absence of the type I error rate in
the sample size calculation meant over a quarter of arti-
cles were not clearly consistent with regard to the type I
error rate and corresponding CI.
Most guidelines advise presenting two-sided 95% CIs
and this is what most articles presented. However, this rec-
ommendation may cause some confusion between equiva-
lence and non-inferiority trials. A 5% signiﬁcance level is
maintained using 95% CIs in equivalence trials for two-
sided hypotheses, whereas non-inferiority takes a one-
sided hypothesis and so a two-sided 90% CI should be cal-
culated. If a one-sided type I error rate of 2.5% is used in
the sample size calculation, then this corresponds to the
stricter two-sided 95% CIs, not a one-sided 95% CI.34
The power and type I error rate should be clearly
reported within sample size calculations and whether
the type I error rate is for a one-sided or two-sided test.
For example, the CAP-START trial used a one-sided sig-
niﬁcance test of 0.05 with two-sided 90% CIs, and the
authors provide exact details of the sample size calcula-
tion in online supplementary appendix.35 If presenting
one bound of the CI throughout an article, this must be
performed clearly and consistently as described by
Schulz-Schüpke et al,36 Lucas et al,37 Gülmezoglu et al.38
Recently, JAMA have introduced a policy to present the
lower bound of the CI with the upper bound tending
towards inﬁnity,39 and this has been put into practice in
recent non-inferiority trials.40–43
It is unclear whether the potential issues surrounding
missing data are well recognised for non-inferiority
studies, given that the majority of articles did not expli-
citly state whether or not methods to handle missing
outcome data would be considered. Most trials that used
multiple imputation stated the number of imputations
used but few discussed the assumptions made, which are
particularly critical in this context. Some missing data
are inevitable, but naive assumptions and/or analysis
threaten trial validity for ITT and PP analyses,14 particu-
larly in the non-inferiority context where more missing
data can bias towards demonstrating non-inferiority.44
It is recommended for trials to clearly report whether
imputation methods to handle missing data were or were
not performed. If imputation was used, it should be clearly
stated what method was used along with any assumptions
made, following the guidelines of Sterne et al.45
Only about a third of articles reviewed reported using
sensitivity analyses. There was some confusion between
sensitivity analyses for missing data and secondary ana-
lyses. Sensitivity analyses for missing data should keep
the primary analysis model, but vary the assumptions
about the distribution of the missing data, to establish
the robustness of inference for the primary analysis to
the inevitably untestable assumptions about the missing
data. In contrast, secondary analysis with regard to
excluding patients for the primary outcome is attempt-
ing to answer a separate, secondary question.46 Thus,
while EMEA 2000 and CONSORT 2012 describe this as
sensitivity analysis (and many papers we reviewed fol-
lowed this), in general this will not be the case, and con-
ﬂating the two inevitably leads to further confusion.
The focus of the analysis for non-inferiority trials
should be on patients who behaved as they were sup-
posed to within a trial, that is the PP population, but
rather than excluding patients from the PP analyses, an
alternative approach would be to make an assumption
about the missing data for patients who do not adhere
to the predeﬁned PP deﬁnition and then impute
missing outcomes for these patients as if they had con-
tinued in the trial without deviating. Sensitivity analyses
should then be used to check robustness of these
results. However, currently, it is unclear what methods
are appropriate to achieve this goal.
Subgroup of trials with published protocols
The mandatory publication of protocols taken from
NEJM publications improved results for all criteria
assessed. This reiterates the ﬁndings from Vale et al47
who evaluated the risk of bias assessments in systematic
reviews assessed from published reports, but had also
accessed protocols directly from the trial investigators
and found that deﬁciencies in the medical journal
reports of trials does not necessarily reﬂect deﬁciencies
in trial quality. Given this, it is clear that a major
improvement in the reporting of non-inferiority trials
would result if all journals followed the practice. Since
publication of e-supplements is very cheap, there
appears to be no reason not to do this.
Strengths and limitations
This research demonstrates the inconsistency in the
recommendations for non-inferiority trials provided by
the available guidelines, which was also reﬂected within
this review. We have provided several recommendations
using examples for researchers wishing to use the non-
inferiority design and have outlined the most important
recommendations that we hope will be taken up in
future guidelines (box 1). We have also highlighted the
importance of missing data and using sensitivity analyses
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speciﬁc to non-inferiority trials. There are also some lim-
itations in this review. First, a justiﬁcation of the choice
of the margin was recorded as such if any attempt was
made to do so. Therefore, one could argue that inad-
equate attempts were counted as a ‘justiﬁcation’;
however, there was good agreement between reviewers
when independently assessed. Second, only one reviewer
extracted information from all articles and therefore
assessments may be subjective. However, there was good
agreement when a random 5% of papers were inde-
pendently assessed, and the categorisation of the justiﬁ-
cation of the non-inferiority margin was also
independently assessed in all papers where a justiﬁcation
was given. Third, an update of the CONSORT statement
for non-inferiority trials was published during the period
of the search in 2012,9 which could improve the report-
ing of non-inferiority trials over the next few years.
However, the ﬁrst CONSORT statement for non-
inferiority trials published in 20061 was released well
before the studies included in our search and we have
found that reporting of non-inferiority trials remains
poor.
CONCLUSION
Our ﬁndings suggest clear violations of available guide-
lines, including the CONSORT 2006 statement (pub-
lished 4 years before the ﬁrst paper in our review),
which concentrate on improving how non-inferiority
trials are reported and is widely endorsed across medical
journals.
There is some indication that the quality of reporting
for non-inferiority studies can affect the conclusions
made and therefore the results of trials that fail to
clearly report the items discussed above should be inter-
preted cautiously. It is essential that justiﬁcation for the
choice of the non-inferiority margin becomes standard
practice, providing the information early on when plan-
ning a study including as much detail as possible. If the
choice of the non-inferiority margin changes following
approval from an ethics committee, justiﬁcation for the
change and changes to the original sample size calcula-
tion should be explicit. If journals enforced a policy
where authors must justify the choice of the non-
inferiority margin prior to accepting publication, this
would encourage authors to provide robust justiﬁcations
for something so critical given that clinical practice
may be expected to change if the margin of non-
inferiority is met.
Sample size calculations include consideration of the
type I error rate, which should be consistent with the
CIs as these provide inferences made for non-inferiority
when compared against the margin. Inconsistency
between the two may distort inferences made, and stric-
ter CIs may lack power to detect true differences for the
original sample size calculation. If any imputation was
performed, then this should be detailed along with its
underlying assumptions, supplemented with sensitivity
analyses under different assumptions about the missing
data. There is an urgent need for research into appro-
priate ways of handling missing data in the PP analysis
for non-inferiority trials; once resolved, this analysis
should be the primary analysis.
Information that is partially prespeciﬁed before the
conduct of a trial may inadvertently provide opportun-
ities to modify decisions that were not prespeciﬁed at
the time of reporting without providing any justiﬁcation.
It is therefore crucial for editors to be satisﬁed that cri-
teria are deﬁned a priori. A compulsory requirement
from journals to publish protocols as e-supplements and
even statistical analysis plans along with the main article
would avoid this ambiguity.
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Box 1 Recommendations
▸ Justification of the margin should be a made mandatory in
journals.
▸ Authors should make reference to preserving the treatment
effect based on estimates of the standard-of-care arm from
previous trials.
▸ Presentation of the CI should be consistent with the type I
error rate used in sample size calculations.
▸ Analyses should be performed to answer the question of inter-
est (ie, the primary outcome) using additional analyses to test
the robustness of that definition, rather than to heedlessly
satisfy intention-to-treat and per-protocol definitions.
▸ Methods to handle missing data should be considered, and
sensitivity analyses should be considered to test the assump-
tions of missing data made on the primary analysis.
▸ Protocols should always be published as online supplementary
material and authors should make use of online supplementary
material to include additional detail on methods (such as
details for justifying the choice of the non-inferiority margin
and full definition of analyses conducted), so that a word limit
for a published article should not be an excuse for poor
reporting.
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